Pacer Advisors
TCRR

Pacer Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Pacer Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,705
Closed -$60K – 1589
2021
Q1 		$60K Buy
2,705
+1,624
+150% +$44.3K ﹤0.01% 1421
2020
Q4 		$33K Buy
+1,081
New +$27.3K ﹤0.01% 1455

Other funds holding TCRR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Pacer Advisors's TCRR Position: Q2 2021 in Review

Pacer Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2021, closing a stake of 2,705 shares — an estimated $60K sold.

Pacer Advisors first reported a position in TCRR in Q4 2020 and held it in 2 quarters. The position peaked at $60K in Q1 2021. 119 funds tracked by Wall St. Rank hold TCRR as of Q2 2021.

  • Pacer Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 2,705 TCR2 Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $60K.
  • Pacer Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Pacer Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $60K in Q1 2021.
  • 119 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.